Ryde Group (RYDE) CEO awarded 3.5M Class B shares, gains majority votes
Rhea-AI Filing Summary
Ryde Group Ltd reported issuing 3,500,000 Class B Ordinary Shares to its founder, chairman and CEO, Terence Zou, under a performance-based award. The milestones were met after a $2 million registered direct offering on December 3, 2025 and a $12 million private offering on December 9, 2025. Class A shares carry one vote each, while Class B shares carry ten votes each. Following this issuance, Zou beneficially owns 19,677,175 Class B shares, representing about 11.59% of total issued and outstanding share capital but about 56.74% of aggregate voting power, based on 169,726,306 total ordinary shares outstanding. The Class B shares are not listed on the NYSE American.
Positive
- None.
Negative
- Founder majority voting control with smaller economic stake: After the grant, the CEO holds about 11.59% of share capital but controls roughly 56.74% of voting power through high-vote Class B shares, limiting other shareholders’ influence.
Insights
CEO’s equity grant cements majority voting control via high-vote shares.
Ryde Group issued 3,500,000 Class B Ordinary Shares to CEO Terence Zou after he met performance milestones tied to a $2 million registered direct offering and a $12 million private offering completed in December 2025.
Class B shares carry ten votes each versus one vote for Class A. After this grant, Zou holds 19,677,175 Class B shares, equal to about 11.59% of total share capital but about 56.74% of aggregate voting power, based on 169,726,306 ordinary shares outstanding.
This structure concentrates control with the founder despite a relatively modest economic stake, which can affect how much influence other shareholders have over corporate decisions. Future governance-related disclosures in company filings will be important to understand how this voting control is exercised.
Key Figures
Key Terms
registered direct offering financial
private offering financial
aggregate voting power financial
foreign private issuer regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.